The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
Kinetic oscillation stimulation for chronic migraine is associated with a significant decrease in monthly headache days vs ...
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
Confusion between approved injectable epinephrine products and unapproved nasal solutions has prompted a warning to ...
Another natural method that may help you find relief from environmental factors behind your post-nasal drip is by inhaling ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...